Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA5 | P11021 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | CMA1 | P23946 | 3/20 | 0.36 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | APAF1 | O14727 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2486672 | 0.84 | AR (0.49) | PTGS1PTGS2POLBMAPTL3MBTL1 | |
| SCHEMBL1366570 | 0.82 | PARP1 (0.38) | PTGS1PTGS2 | |
| SCHEMBL1367124 | 0.78 | L3MBTL1 (0.38) | PTGS1PTGS2POLBL3MBTL1 | |
| SCHEMBL14999720 | 0.77 | AKR1B1 (0.57) | HSPA5AKR1B1KDM4EMAPTCYP1A2 | |
| SCHEMBL1369734 | 0.77 | SLC1A5 (0.49) | POLBKDM4EMAPT | |
| SCHEMBL1369142 | 0.76 | KDR (0.47) | MAPT | |
| SCHEMBL1369203 | 0.70 | RAB9A (0.51) | MAPT | |
| SCHEMBL17491866 | 0.69 | PTGS2 (0.50) | AKR1B1PTGS1PTGS2POLBKDM4E | |
| SCHEMBL27600409 | 0.68 | SLC7A5 (0.44) | PTGS1PTGS2 | |
| SCHEMBL153695 | 0.68 | PTGS2 (0.59) | PTGS1PTGS2POLBKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288293-A1 | ISOQUINOLINE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-11-24 | — | — | US | disclosed |
| EP-2377851-A1 | ISOQUINOLINE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2011-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288293-A1 | ISOQUINOLINE DERIVATIVE | HRH1, HRH2, HRH4 | HSPA5 2155/4885AKR1B1 1246/4885PTGS1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.